Australia's most trusted
source of pharma news
Posted 19 November 2025 PM
CSL will spend about US$1.5 billion on expanding its US manufacturing facilities, joining a long line of pharma companies expanding their US footprint in the wake of Donald Trump’s tariff threats.
The investment over the next five years will create hundreds of jobs, strengthen US manufacturing capabilities for plasma-derived therapies, and help secure the US medicine supply chain, reflecting the company’s commitment to meet the growing clinical need for immunoglobulin over the long term, CSL said.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.